Q3 Earnings Estimate for CNTA Issued By Leerink Partnrs

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Centessa Pharmaceuticals in a research note issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of ($0.40) for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($2.06) EPS and FY2029 earnings at $0.49 EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04.

A number of other equities analysts have also issued reports on CNTA. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Trading Down 0.2 %

NASDAQ:CNTA opened at $14.51 on Thursday. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -9.48 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The business has a fifty day moving average of $16.49 and a 200-day moving average of $16.41.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after acquiring an additional 685,371 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after purchasing an additional 924,027 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Centessa Pharmaceuticals by 24.3% in the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock worth $58,603,000 after buying an additional 684,391 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 26.2% during the fourth quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after buying an additional 710,936 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now directly owns 118,265 shares of the company’s stock, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the sale, the insider now directly owns 159,782 shares in the company, valued at $2,631,609.54. This trade represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 260,168 shares of company stock worth $4,309,568. Corporate insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.